No black box warning on record for Retacrit

As of the latest FDA labeling reviewed, Retacrit (EPOETIN ALFA-EPBX) does not carry a black box warning. Standard warnings and precautions still apply — see the full Retacrit medicine page for the complete safety profile.

Other warnings & precautions

5 WARNINGS AND PRECAUTIONS • Increased Mortality, Myocardial Infarction, Stroke, and Thromboembolism: Using ESAs to target a hemoglobin level of greater than 11 g/dL increases the risk of serious adverse cardiovascular reactions and has not been shown to provide additional benefit ( 5.1 and 14.1 ). Use caution in patients with coexistent cardiovascular disease and stroke ( 5.1 ). • Increased Morta

No black box warning on record for Retacrit

Other warnings & precautions

5 WARNINGS AND PRECAUTIONS • Increased Mortality, Myocardial Infarction, Stroke, and Thromboembolism: Using ESAs to target a hemoglobin level of greater than 11 g/dL increases the risk of serious adverse cardiovascular reactions and has not been shown to provide additional benefit ( 5.1 and 14.1 ). Use caution in patients with coexistent cardiovascular disease and stroke ( 5.1 ). • Increased Morta

Retacrit Black Box Warning

No black box warning on record for Retacrit

Other warnings & precautions

Retacrit Black Box Warning

No black box warning on record for Retacrit

Other warnings & precautions